KORU MEDICAL SYSTEMS INC (KRMD) Stock News

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -50% and 6.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: DRIO

KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

Earnings Scheduled For May 7, 2025

Mentions: XPER EMR BLZE ERII ...

KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025

Analyst Expectations For KORU Medical Systems's Future

KRMD Stock Earnings: KORU Medical Systems Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips KORU Medical Systems (NASDAQ:KRMD) just reported results for the first quarter ...

KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance

KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System

KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

KORU Medical Systems to Participate in Piper Sandler’s 36th Annual Healthcare Conference

KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance

KORU Medical Systems to Participate in Upcoming Investor Conferences

KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion

KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024

KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

KORU Medical Systems, Inc Announces Leadership Changes to Support Growth Agenda

KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

KRMD Stock Earnings: KORU Medical Systems Beats EPS, Beats Revenue for Q1 2024

KRMD stock results show that KORU Medical Systems beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements.

Mentions: ARBE PWFL PRTS LTRX ...

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance